- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Small Step for Pfizer's Biosimilars; Leap for Its COVID-19 Vaccine
Pfizer reported strong sales for its biosimilars portfolio, but these were eclipsed by the massive success of the company's mRNA vaccine for COVID-19.
Pfizer reported second-quarter 2021 biosimilar revenues up 88% from the comparable second quarter of 2020. These were dwarfed, however, by sales of the Pfizer-BioNTech COVID-19 vaccine.
Biosimilar sales for the second quarter of 2021 were $559 million globally, primarily fueled by the launches of bevacizumab (Zirabev), rituximab (Ruxience), and trastuzumab (Trazimera) biosimilars.
The company also reported ongoing growth in sales of its epoetin alfa biosimilar (Retacrit) in the United States. Retacrit was launched in 2018 and remains the only epoetin biosimilar in the United States.
Pfizer also reported a 19% decline in global sales of its etanercept originator product (Enbrel) owing to biosimilar competition in Europe and Japan. Enbrel does not yet face biosimilar competition in the United States.
Although growth in biosimilar sales at Pfizer has been robust over the past year, the company’s core business focus is now commercialization of its mRNA COVID-19 vaccine (BNT162b2) and regulatory interaction globally to broaden access and flexibility for use of this product.
Pfizer said it anticipates 2021 revenues of $33.5 billion for BNT162b2, which reflects 2.1 billion doses that Pfizer had contracted to deliver as of mid-July 2021. The company reported overall second quarter 2021 revenues of $19 billion, up 86% from the comparable 2020 quarter.
Without the COVID-19 vaccine, Pfizer’s revenues would have climbed just 10% overall, to $11.1 billion, the company said.
For a report on the company’s first quarter 2021 revenues, click here.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
